speb/financial-data huggingface dataset:
CONCOR.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 4173300000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Other Properties: 71631500000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 71631500000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 205000000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 205000000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 31176600000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 31176600000.00
CONCOR.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
CONCOR.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Payables: 2346900000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Payables: 2346900000.00
CONCOR.NS income_statement (annual, 2026-03-31) — Pretax Income: 16209000000.00
CONCOR.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 3417100000.00
CONCOR.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 0.00
CONCOR.NS cash_flow (annual, 2026-03-31) — Purchase Of Intangibles: -102400000.00
CONCOR.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -11387800000.00
CONCOR.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 61465500000.00
CONCOR.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 15716200000.00
CONCOR.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 6155300000.00
CONCOR.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: 0.00
CONCOR.NS cash_flow (annual, 2026-03-31) — Sale Of Intangibles: 34900000.00
CONCOR.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 5176000000.00
CONCOR.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 69200000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Share Issued: 761617935.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 761617935.00
CONCOR.NS income_statement (annual, 2026-03-31) — Special Income Charges: 0.00
CONCOR.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 129423500000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 129423500000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 129281300000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 129281300000.00
CONCOR.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
CONCOR.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
CONCOR.NS income_statement (annual, 2026-03-31) — Tax Provision: 4050300000.00
CONCOR.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 824200000.00
CONCOR.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.25
CONCOR.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.24
CONCOR.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 32200000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 32200000.00
CONCOR.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -3736800000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Total Assets: 151756600000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 151756600000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 129666400000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 129666400000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Total Debt: 9645700000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 9645700000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 130523700000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 130523700000.00
CONCOR.NS income_statement (annual, 2026-03-31) — Total Expenses: 77445800000.00
CONCOR.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 19889500000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 21232900000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 21232900000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 104132600000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 104132600000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 9086800000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 9086800000.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 0.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 0.00
CONCOR.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 0.00
CONCOR.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
CONCOR.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
CONCOR.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
CONCOR.NS balance_sheet (annual, 2026-03-31) — Working Capital: 35477900000.00
CONCOR.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 35477900000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — +Operating Expense: 2943900000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — +Total Revenue: 7084400000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Accounts Payable: 831060000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Accounts Receivable: 2321740000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -1378490000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 829220000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -7810000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Amortization: 33950000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 33950000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 104616204.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Basic EPS: 16.72
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Beginning Cash Position: 51440000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 2240020000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Capital Expenditure: -1555050000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Capital Lease Obligations: 19070000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Capital Stock: 95110000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Cash And Cash Equivalents: 6670000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Cash Cash Equivalents And Short Term Investments: 1617750000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Cash Dividends Paid: -705210000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 0.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 6670000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Change In Inventory: -415090000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Change In Other Current Assets: 241700000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Change In Other Current Liabilities: 114060000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Change In Payable: 365320000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Change In Receivables: -527690000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Change In Working Capital: -220530000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Changes In Cash: -44770000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Common Stock: 95110000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Common Stock Equity: 11032230000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Construction In Progress: 741560000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Cost Of Revenue: 1779230000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Current Assets: 6326660000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Current Capital Lease Obligation: 15960000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Current Debt: 293380000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Current Debt And Capital Lease Obligation: 309340000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Current Liabilities: 1551680000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Current Provisions: 17480000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Depreciation: 466550000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Depreciation And Amortization: 500500000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Depreciation And Amortization In Income Statement: 500500000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Depreciation Income Statement: 466550000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 104616204.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Diluted EPS: 16.72
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Diluted NI Availto Com Stockholders: 1749290000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — EBIT: 2430020000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — EBITDA: 2930520000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — End Cash Position: 6670000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 2560000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Financing Cash Flow: -1001640000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 221880000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Free Cash Flow: 519700000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Gain Loss On Investment Securities: -52300000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Gain Loss On Sale Of PPE: 340000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 105810000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Goodwill And Other Intangible Assets: 35790000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 2329550000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Gross PPE: 7814040000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Gross Profit: 5305170000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Hedging Assets Current: 4980000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Interest Expense: 54840000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Interest Expense Non Operating: 54840000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Interest Income: 47870000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 47870000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Interest Paid Cff: -53150000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Interest Received Cfi: 41390000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Inventory: 1951170000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Invested Capital: 11638090000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Investing Cash Flow: -1117880000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Investmentin Financial Assets: 2560000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Investmentsin Joint Venturesat Cost: 0.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Issuance Of Debt: 0.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 547110000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Long Term Capital Lease Obligation: 3110000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Long Term Debt: 312480000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Long Term Debt And Capital Lease Obligation: 315590000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Long Term Debt Issuance: 0.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Long Term Debt Payments: -250020000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Long Term Equity Investment: 0.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 3853170000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Net Debt: 599190000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Net Foreign Currency Exchange Gain Loss: -18350000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Net Income: 1749290000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Net Income Common Stockholders: 1749290000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Net Income Continuous Operations: 1749290000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Net Income From Continuing And Discontinued Operation: 1749290000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Net Income From Continuing Operation Net Minority Interest: 1749290000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Net Income From Continuing Operations: 2375180000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Net Income Including Noncontrolling Interests: 1749290000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Net Interest Income: -13480000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Net Investment Purchase And Sale: 395220000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Net Issuance Payments Of Debt: -257630000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Net Long Term Debt Issuance: -250020000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Net Non Operating Interest Income Expense: -13480000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Net Other Financing Charges: 30890000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Net PPE: 6435550000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Net PPE Purchase And Sale: -1554490000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Net Short Term Debt Issuance: -7610000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Net Tangible Assets: 10996440000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Liabilities: 209710000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 18740000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 284430000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Normalized EBITDA: 2940070000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Normalized Income: 1756323575.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Operating Cash Flow: 2074750000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Operating Income: 2361270000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Operating Revenue: 7084400000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Ordinary Shares Number: 104616204.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Other Intangible Assets: 35790000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Other Non Cash Items: -22400000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Other Non Operating Income Expenses: 9730000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Other Operating Expenses: 1264900000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Other Payable: 236960000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Other Properties: 432180000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 268890000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Other Short Term Investments: 1611080000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Other Special Charges: -2690000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Payables: 1068020000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 17480000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 151980000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Pretax Income: 2375180000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Provisionand Write Offof Assets: 19240000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Purchase Of Investment: -5219140000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Purchase Of PPE: -1555050000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 827490000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Reconciled Cost Of Revenue: 1779230000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Reconciled Depreciation: 500500000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 20000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 20000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Repayment Of Debt: -250020000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 10150000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 9815720000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Sale Of Investment: 5614360000.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Sale Of PPE: 560000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 214360000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 320170000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Share Issued: 104616204.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Special Income Charges: -61850000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Stockholders Equity: 11032230000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Tangible Book Value: 10996440000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Tax Effect Of Unusual Items: -2516425.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Tax Provision: 625890000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Tax Rate For Calcs: 0.26
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Taxes Receivable: 0.00
CONCORDBIO.NS cash_flow (annual, 2022-03-31) — Taxes Refund Paid: -607850000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Total Assets: 13127950000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Total Capitalization: 11344710000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Total Debt: 624930000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Total Equity Gross Minority Interest: 11032230000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Total Expenses: 4723130000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Total Liabilities Net Minority Interest: 2095720000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Total Non Current Assets: 6801290000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Total Non Current Liabilities Net Minority Interest: 544040000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 6510000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Total Tax Payable: 0.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Total Unusual Items: -9550000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: -9550000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Work In Process: 901800000.00
CONCORDBIO.NS balance_sheet (annual, 2022-03-31) — Working Capital: 4774980000.00
CONCORDBIO.NS income_statement (annual, 2022-03-31) — Write Off: 64540000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — +Operating Expense: 3288198000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — +Total Revenue: 8306322000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 938000000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 2737576000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -1873062000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 819710000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -8730000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Amortization: 33794000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 33794000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 104616204.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Basic EPS: 22.95
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 6669000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 2465453000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -1450848000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 3107000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 104616000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 34992000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 1811159000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -535635000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 34992000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -172273000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -191310000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: -92053000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Change In Payable: 98806000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -430971000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -522855000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Changes In Cash: 28323000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Common Stock: 104616000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Common Stock Dividend Paid: -535635000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 12900025000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 1803166000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 1970667000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Current Assets: 7277001000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 1469000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Current Debt: 250000000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 251469000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 1918443000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 274757000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Depreciation: 506530000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 540324000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 540324000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 506530000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 104616204.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Diluted EPS: 22.95
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 2400857000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — EBIT: 3265237000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — EBITDA: 3805561000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — End Cash Position: 34992000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 1246000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -852194000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 148019000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 1009170000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -37169000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 940000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 105019000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 1977000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 2746306000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 9604053000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Gross Profit: 6335655000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Hedging Assets Current: 2500000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Interest Expense: 45103000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 45103000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Interest Income: 44408000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 44408000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -39582000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 55849000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Inventory: 2123147000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 13212381000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -1579501000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 1246000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Investmentsin Joint Venturesat Cost: 0.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 0.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 547111000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 1638000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 62356000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 63994000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 0.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -250000000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 0.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 4294524000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Net Debt: 277364000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 19535000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Net Income: 2400857000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 2400857000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 2400857000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 2400857000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 2400857000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 3220134000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 2400857000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Net Interest Income: -7437000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -184755000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -293372000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -250000000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -7437000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: 32356000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Net PPE: 7730991000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -1450595000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: -43372000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 12898048000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 234390000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 22966000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 92938000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 3763127000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Normalized Income: 2369286104.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 2460018000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Operating Income: 3047457000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Operating Revenue: 8306322000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 104616204.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 7116000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 1977000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 7891000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -21947000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 15872000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 1551033000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Other Payable: 334552000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Other Properties: 493799000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 383549000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 1776167000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Other Special Charges: -5265000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Payables: 1362539000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 274760000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 211954000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Pretax Income: 3220134000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: -16585000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -6430992000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -1450848000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 835255000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 1970667000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 540324000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 58980000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 58980000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -250000000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 93680000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 11683520000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 6246237000.00
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 253000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 236985000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 342004000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Share Issued: 104616204.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Special Income Charges: 5265000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 12900025000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 12898048000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 10863104.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Tax Provision: 819277000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.26
CONCORDBIO.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -702766000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Total Assets: 15139818000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 12962381000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Total Debt: 315463000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 12900025000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Total Expenses: 5258865000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 2239793000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 7862817000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 321350000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 6742000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 89987000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 42434000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 42434000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Work In Process: 1131982000.00
CONCORDBIO.NS balance_sheet (annual, 2023-03-31) — Working Capital: 5358558000.00
CONCORDBIO.NS income_statement (annual, 2023-03-31) — Write Off: 0.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — +Operating Expense: 3701646000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — +Total Revenue: 9980573000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 944353000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 3496089000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -2384583000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 819710000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -13907000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Amortization: 3388000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 3388000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 49695000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 104616204.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Basic EPS: 29.45
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 34992000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 2608312000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -856885000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 35078000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 104616000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 151421000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 2855328000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -714529000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 151421000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 43609000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 3329000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 61309000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Change In Payable: -112866000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -786596000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -811798000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 116429000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Common Stock: 104616000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: -714529000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 15266455000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 2194623000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 2416100000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Current Assets: 8962311000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 16208000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Current Debt: 62298000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 78506000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 1421554000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 39019000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Depreciation: 535915000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 535915000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 535915000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 532527000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 104616204.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Diluted EPS: 29.45
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 3081032000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — EBIT: 4151169000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — EBITDA: 4687084000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — End Cash Position: 151421000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 0.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -992149000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 165978000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 1797786000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -140647000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -119000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 111287000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 3197000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 3509996000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 10329167000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Gross Profit: 7564473000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 1212000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Interest Expense: 25519000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 25519000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Interest Income: 30411000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 30411000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -26496000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 27728000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Inventory: 2079538000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 15328753000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -1546093000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 0.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Investmentsin Joint Venturesat Cost: 20586000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 547111000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 18870000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 0.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 18870000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -250058000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 20586000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 19561000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 4459176000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: 22254000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Net Income: 3081032000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 3081032000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 3081032000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 3081032000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 3081032000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 4125650000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 3081032000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Net Interest Income: -1429000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -718687000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -250058000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -250058000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -1429000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: 13912000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Net PPE: 7944584000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -855134000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 0.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 15263258000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 280645000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 19561000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 31507000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 4544904000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Normalized Income: 2974852093.86
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 2654671000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Operating Income: 3862827000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Operating Revenue: 9980573000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 104616204.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 284933000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 62675000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 15161839000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 3197000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 6975000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -15688000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 79799000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 23554000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 1669538000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Payable: 267122000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Properties: 519945000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 188839000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 2703907000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Other Special Charges: -1533000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Payables: 1266413000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 284552000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Pretax Income: 4125650000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 6313000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -8381000000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -856885000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 671783000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 2416100000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 535915000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 85581000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 85581000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -250058000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 56753000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 14049950000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 7662313000.00
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 1751000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 331096000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 442383000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Share Issued: 104616204.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Special Income Charges: 1533000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 15266455000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 15263258000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 36000093.86
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Tax Provision: 1044618000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.25
CONCORDBIO.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -1033496000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Total Assets: 17007085000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 15266455000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Total Debt: 97376000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 15266455000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Total Expenses: 6117746000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 1740630000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 8044774000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 319076000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 6321000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 54938000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 142180000.00
CONCORDBIO.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 142180000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 0.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Work In Process: 1234802000.00
CONCORDBIO.NS balance_sheet (annual, 2024-03-31) — Working Capital: 7540757000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 821715000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 3444457000.00